Australia's Reece Pharmaceuticals rises on research and development deal with US Army

Recce Pharmaceuticals

02/02/2026 04:14

** Shares of Australia's Recce Pharmaceuticals RCE.AX rise as much as 8.9% to A$0.61

** Stock on track for its best session since December 3, 2025, if gains hold

** Stock saps a four-session losing streak, and last up 3.6%

** The pharmaceutical co signs a second cooperative research and development agreement with the U.S. Army Institute of Surgical Research

** Agreement to conduct study to evaluate effectiveness of RECCE 327 gel in reducing bioburden burn wounds

** Stock is down 10.8%, YTD

 (Reporting by Anjali Singh in Bengaluru)

 ((anjali.singh2@thomsonreuters.com;))